- KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations
- KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations
- KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous non-small cell lung carcinoma in adults
- KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma in adults whose tumours express PD-L1 with a ≥1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA
An introduction to module one of the Peer-to-Peer KEYLearning video series
Length: 00:59 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
The role of PD-L1 testing in selecting patients for immunotherapy plus chemotherapy
Length: 08:46 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Explaining the mode of action of KEYTRUDA (pembrolizumab) plus chemotherapy combination therapy to patients
Length: 08:31 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Using KEYTRUDA (pembrolizumab) plus chemotherapy in patients with pre-existing autoimmune disease
Length: 03:42 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Overview of immune-related adverse events in patients treated with KEYTRUDA plus chemotherapy
Length: 09:53 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Extending guidance for managing chemotherapy-related adverse events to include immune-related adverse events
Length: 07:20 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Distinguishing between an immunotherapy and chemotherapy-related adverse event
Length: 07:28 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Supporting patients through the transition at the end of their KEYTRUDA (pembrolizumab) plus chemotherapy treatment
Length: 06:45 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
A Summary of module one of the Peer-to-Peer KEYLearning video series
Length: 01:04 | This video is best viewed in full screen, using the button in the bottom right
Further information
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]